| Kelly Ann Riggieri, APRN | |
|
345 N Main St, Suite 245, West Hartford, CT 06117-2515 | |
| (860) 236-3000 | |
| (860) 236-3002 |
| Full Name | Kelly Ann Riggieri |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 9 Years |
| Location | 345 N Main St, West Hartford, Connecticut |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1073981841 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LF0000X | Nurse Practitioner - Family | 6274 (Connecticut) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Francis Hospital & Medical Center | Hartford, CT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Trinity Health Of New England Provider Network Organization Inc | 0941113567 | 621 |
News Archive
DePuy Synthes Companies announced the addition of four new products to its adult deformity portfolio as well as a new education offering, continuing its expansion of one of the broadest spine portfolios in the industry. The products were displayed by DePuy Synthes Spine at the 81st annual meeting of the American Academy of Orthopaedic Surgeons.
Bayer Inc. today responded to Professor Marvin Meyer's letter to the editor, entitled: "Critical questions concerning the validity of the Bayer study report of differences in bioavailability between 60 mg of nifedipine osmotic push-pull systems after fasted and fed administration" and published in the online edition of the International Journal of Clinical Pharmacology and Therapeutics. Bayer responded to the clinical relevance of the differences in formulation and dissolution behaviour and the delayed absorption of Mylan's extended release nifedipine.
Protective immune memory-through B cells, which make antibodies, and/or T cells, which in the case of CD8+ T cells can kill virus-infected cells-can be induced by identical but also by related viruses.
A lipid metabolite called 12,13-diHOME is in human breast milk and appears to be associated with beneficial infant weight gain and body composition in the early postnatal period.
Tumor treatment with multispecific antibodies is significantly more tolerable if administered subcutaneously rather than via the bloodstream, which was the standard procedure until now. This was the result of an animal model study undertaken by researchers at Helmholtz Zentrum München in cooperation with the Munich biotech company Trion Research.
› Verified 8 days ago
| Entity Name | Trinity Health Of New England Provider Network Organization Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1003882812 PECOS PAC ID: 0941113567 Enrollment ID: O20031110000651 |
News Archive
DePuy Synthes Companies announced the addition of four new products to its adult deformity portfolio as well as a new education offering, continuing its expansion of one of the broadest spine portfolios in the industry. The products were displayed by DePuy Synthes Spine at the 81st annual meeting of the American Academy of Orthopaedic Surgeons.
Bayer Inc. today responded to Professor Marvin Meyer's letter to the editor, entitled: "Critical questions concerning the validity of the Bayer study report of differences in bioavailability between 60 mg of nifedipine osmotic push-pull systems after fasted and fed administration" and published in the online edition of the International Journal of Clinical Pharmacology and Therapeutics. Bayer responded to the clinical relevance of the differences in formulation and dissolution behaviour and the delayed absorption of Mylan's extended release nifedipine.
Protective immune memory-through B cells, which make antibodies, and/or T cells, which in the case of CD8+ T cells can kill virus-infected cells-can be induced by identical but also by related viruses.
A lipid metabolite called 12,13-diHOME is in human breast milk and appears to be associated with beneficial infant weight gain and body composition in the early postnatal period.
Tumor treatment with multispecific antibodies is significantly more tolerable if administered subcutaneously rather than via the bloodstream, which was the standard procedure until now. This was the result of an animal model study undertaken by researchers at Helmholtz Zentrum München in cooperation with the Munich biotech company Trion Research.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Kelly Ann Riggieri, APRN 46 Yale Dr, Manchester, CT 06042-8504 Ph: (401) 316-3605 | Kelly Ann Riggieri, APRN 345 N Main St, Suite 245, West Hartford, CT 06117-2515 Ph: (860) 236-3000 |
News Archive
DePuy Synthes Companies announced the addition of four new products to its adult deformity portfolio as well as a new education offering, continuing its expansion of one of the broadest spine portfolios in the industry. The products were displayed by DePuy Synthes Spine at the 81st annual meeting of the American Academy of Orthopaedic Surgeons.
Bayer Inc. today responded to Professor Marvin Meyer's letter to the editor, entitled: "Critical questions concerning the validity of the Bayer study report of differences in bioavailability between 60 mg of nifedipine osmotic push-pull systems after fasted and fed administration" and published in the online edition of the International Journal of Clinical Pharmacology and Therapeutics. Bayer responded to the clinical relevance of the differences in formulation and dissolution behaviour and the delayed absorption of Mylan's extended release nifedipine.
Protective immune memory-through B cells, which make antibodies, and/or T cells, which in the case of CD8+ T cells can kill virus-infected cells-can be induced by identical but also by related viruses.
A lipid metabolite called 12,13-diHOME is in human breast milk and appears to be associated with beneficial infant weight gain and body composition in the early postnatal period.
Tumor treatment with multispecific antibodies is significantly more tolerable if administered subcutaneously rather than via the bloodstream, which was the standard procedure until now. This was the result of an animal model study undertaken by researchers at Helmholtz Zentrum München in cooperation with the Munich biotech company Trion Research.
› Verified 8 days ago
Erin Hannan, NP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 345 N Main St, Suite 248, West Hartford, CT 06117 Phone: 860-231-8345 Fax: 860-523-4061 | |
Marina Creed, APRN, FNP-BC Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 87 Outlook Ave, West Hartford, CT 06119 Phone: 860-888-6032 Fax: 860-888-6032 | |
Ms. Keira S Ledoux, CPNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 345 N Main St Ste 248, West Hartford, CT 06117 Phone: 860-231-8345 | |
Ms. Jessica L Haggett, APRN Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 1001 Farmington Ave, West Hartford, CT 06107 Phone: 860-213-8365 | |
Mrs. Stephanie Lajeunesse, FNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 1245 New Britain Ave, West Hartford, CT 06110 Phone: 860-234-3325 | |
Ms. Camille Margaux Karalekas, APRN Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 7 N Main St, West Hartford, CT 06107 Phone: 860-206-9552 Fax: 860-206-9554 |